| |
|
|
Llovet Bayer, Josep M
|
|
|
ICREA Research Professor at IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer). Life & Medical Sciences
|
Josep Llovet, MD is Professor of Research-ICREA at the BCLC Group, Liver Unit, IDIBAPS, Hospital Clinic of Barcelona and Professor of Medicine and Director of the HCC Program at the Mount Sinai School of Medicine, New York. He has published 161 manuscripts in clinical and translational research in hepatocellular carcinoma (HCC), including NEJM, Lancet, Nature Genetics, Nature Biotech, Cancer Cell, Gastroenterology and Hepatology (Impact factor: 1520; personal citations:15932; h-index:53). He is President of the International Liver Cancer Association (ILCA), Senior Editor of Clinical Can Res, Journal of Hepatology, has lectured in 350 international meetings and is the Principal Investigator of an Euopean FP-HEPTROMIC, NIH-NIDDK R01-award, I+D grant and several competitive private grants. His achievements are: 1. Establish a clinical and molecular classification for HCC; 2. Establish efficacy of chemoembolization and sorafenib for HCC. 3. Identification of novel pathways in HCC.
|
Research Interests
|
|
|
Prof Josep M Llovet has been working in the clinical and translational research area of hepatocellular carcinoma (HCC) during the last 15 years. He is currently leading international randomized trials in HCC on novel targeted therapies and working in developing a molecular classification of the disease, understanding the genetic aberrations and signaling pathways involved in hepatocarcinogenesis and in the identification of new molecular targeted therapies. For that purpose he has organized the HCC Genomic Consortium, which include 4 centers: IDIBAPS-Hospital Clínic (Barcelona), Mount Sinai (New York), Dana-Farber-MIT-Broad Institute (Boston) and NCI (Milan), and the HEPTROMIC European Consortium funded by an FP-7 Grant
|
| |
KeyWords
|
|
|
Hepatocellular carcinoma; signal transduction pathways; molecular targeted therapies; molecular classification; trial design; genomics; gene signatures; translational research; mTOR signaling; Wnt signaling; IGF signaling; miRNA; nanooncology
|
| |
|